Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Tuesday, April 1, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a clinical stage gene editing company, will participate in the 24th Annual Needham Virtual Healthcare Conference. The company utilizes its proprietary ARCUS platform to develop various in vivo gene editing therapies, including gene elimination, insertion, and excision programs. This participation underscores the company's commitment to advancing gene editing technologies.
Price reaction · baseline $4.77 (2025-03-31 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-5.9%
day 1
-1.7%
day 3
-3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable healthcare conference
  • Showcases Precision BioSciences' innovative ARCUS platform
  • Highlights company's focus on gene editing therapies

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Apr. 1, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today

Frequently Asked Questions

What is the focus of Precision BioSciences?

Precision BioSciences focuses on developing in vivo gene editing therapies.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing.

When is the Needham Virtual Healthcare Conference?

The conference is scheduled for April 1, 2025.

What types of gene editing does Precision BioSciences perform?

They perform gene elimination, insertion, and excision programs.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform Needham Conference
Last updated: Apr 1, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →